Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Evaluation of Oatp and Mrp2 activities in hepatobiliary excretion using newly developed positron emission tomography tracer [11C]dehydropravastatin in rats.

Shingaki T, Takashima T, Ijuin R, Zhang X, Onoue T, Katayama Y, Okauchi T, Hayashinaka E, Cui Y, Wada Y, Suzuki M, Maeda K, Kusuhara H, Sugiyama Y, Watanabe Y.

J Pharmacol Exp Ther. 2013 Oct;347(1):193-202. doi: 10.1124/jpet.113.206425. Epub 2013 Aug 7.

2.

A Clinical Quantitative Evaluation of Hepatobiliary Transport of [11C]Dehydropravastatin in Humans Using Positron Emission Tomography.

Kaneko K, Tanaka M, Ishii A, Katayama Y, Nakaoka T, Irie S, Kawahata H, Yamanaga T, Wada Y, Miyake T, Toshimoto K, Maeda K, Cui Y, Enomoto M, Kawamura E, Kawada N, Kawabe J, Shiomi S, Kusuhara H, Sugiyama Y, Watanabe Y.

Drug Metab Dispos. 2018 May;46(5):719-728. doi: 10.1124/dmd.118.080408. Epub 2018 Mar 19.

PMID:
29555827
3.

Positron emission tomography studies using (15R)-16-m-[11C]tolyl-17,18,19,20-tetranorisocarbacyclin methyl ester for the evaluation of hepatobiliary transport.

Takashima T, Nagata H, Nakae T, Cui Y, Wada Y, Kitamura S, Doi H, Suzuki M, Maeda K, Kusuhara H, Sugiyama Y, Watanabe Y.

J Pharmacol Exp Ther. 2010 Nov;335(2):314-23. doi: 10.1124/jpet.110.170092. Epub 2010 Aug 17.

4.
5.

Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans.

Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y.

Drug Metab Dispos. 2006 Jul;34(7):1247-54. Epub 2006 Apr 19.

6.

Estimation of transporters involved in the hepatobiliary transport of TA-0201CA using sandwich-cultured rat hepatocytes from normal and multidrug resistance-associated protein 2-deficient rats.

Fukuda H, Ohashi R, Ohashi N, Yabuuchi H, Tamai I.

Drug Metab Dispos. 2010 Sep;38(9):1505-13. doi: 10.1124/dmd.110.033258. Epub 2010 Jun 10.

7.

Effects of High-cholesterol Diet on Pravastatin Disposition in the Perfused Rat Liver.

Kawase A, Handa A, Iwaki M.

Eur J Drug Metab Pharmacokinet. 2017 Jun;42(3):519-526. doi: 10.1007/s13318-016-0367-9.

PMID:
27511381
8.

PET imaging-based evaluation of hepatobiliary transport in humans with (15R)-11C-TIC-Me.

Takashima T, Kitamura S, Wada Y, Tanaka M, Shigihara Y, Ishii H, Ijuin R, Shiomi S, Nakae T, Watanabe Y, Cui Y, Doi H, Suzuki M, Maeda K, Kusuhara H, Sugiyama Y, Watanabe Y.

J Nucl Med. 2012 May;53(5):741-8. doi: 10.2967/jnumed.111.098681. Epub 2012 Apr 12.

10.

Lack of Contribution of Multidrug Resistance-associated Protein and Organic Anion-transporting Polypeptide to Pharmacokinetics of Regorafenib, a Novel Multi-Kinase Inhibitor, in Rats.

Hotta K, Ueyama J, Tatsumi Y, Tsukiyama I, Sugiura Y, Saito H, Matsuura K, Hasegawa T.

Anticancer Res. 2015 Sep;35(9):4681-9.

PMID:
26254357
11.

Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human.

Kalgutkar AS, Feng B, Nguyen HT, Frederick KS, Campbell SD, Hatch HL, Bi YA, Kazolias DC, Davidson RE, Mireles RJ, Duignan DB, Choo EF, Zhao SX.

Drug Metab Dispos. 2007 Nov;35(11):2111-8. Epub 2007 Aug 8.

12.

Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury.

Li X, Zhong K, Guo Z, Zhong D, Chen X.

Drug Metab Dispos. 2015 Nov;43(11):1751-9. doi: 10.1124/dmd.115.064121. Epub 2015 Aug 14.

13.

OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker.

Nakagomi-Hagihara R, Nakai D, Kawai K, Yoshigae Y, Tokui T, Abe T, Ikeda T.

Drug Metab Dispos. 2006 May;34(5):862-9. Epub 2006 Feb 24.

14.

OATP and MRP2-mediated hepatic uptake and biliary excretion of eprosartan in rat and human.

Sun P, Wang C, Liu Q, Meng Q, Zhang A, Huo X, Sun H, Liu K.

Pharmacol Rep. 2014 Apr;66(2):311-9. doi: 10.1016/j.pharep.2014.02.013. Epub 2014 Mar 10.

PMID:
24911086
15.

Synthesis of [(11)C]dehydropravastatin, a PET probe potentially useful for studying OATP1B1 and MRP2 transporters in the liver.

Ijuin R, Takashima T, Watanabe Y, Sugiyama Y, Suzuki M.

Bioorg Med Chem. 2012 Jun 15;20(12):3703-9. doi: 10.1016/j.bmc.2012.04.051. Epub 2012 Apr 30.

PMID:
22607882
16.

How organic anions accumulate in hepatocytes lacking Mrp2: evidence in rat liver.

Millet P, Moulin M, Stieger B, Daali Y, Pastor CM.

J Pharmacol Exp Ther. 2011 Mar;336(3):624-32. doi: 10.1124/jpet.110.175406. Epub 2010 Dec 2.

17.

Transport mechanisms of hepatic uptake and bile excretion in clinical hepatobiliary scintigraphy with 99mTc-N-pyridoxyl-5-methyltryptophan.

Kobayashi M, Nakanishi T, Nishi K, Higaki Y, Okudaira H, Ono M, Tsujiuchi T, Mizutani A, Nishii R, Tamai I, Arano Y, Kawai K.

Nucl Med Biol. 2014 Apr;41(4):338-42. doi: 10.1016/j.nucmedbio.2014.01.004. Epub 2014 Jan 13.

PMID:
24607436
18.

Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinemic rats.

Yamazaki M, Kobayashi K, Sugiyama Y.

Biopharm Drug Dispos. 1996 Oct;17(7):607-21. Erratum in: Biopharm Drug Dispos 1997 Jan;18(1):i.

PMID:
8894118
19.
20.

The hepatobiliary disposition of timosaponin b2 is highly dependent on influx/efflux transporters but not metabolism.

Sheng J, Tian X, Xu G, Wu Z, Chen C, Wang L, Pan L, Huang C, Pan G.

Drug Metab Dispos. 2015 Jan;43(1):63-72. doi: 10.1124/dmd.114.059923. Epub 2014 Oct 21.

Supplemental Content

Support Center